title: Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician.
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ.
authors.forename: Graham M
authors.initials: GM
authors.lastname: Lohrmann
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ.
authors.forename: Danish
authors.initials: D
authors.lastname: Atwal
authors.affiliation: Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address: yiandoc@hotmail.com.
authors.forename: John G
authors.initials: JG
authors.lastname: Augoustides
authors.affiliation: Department of Anesthesiology, Mayo Clinic, Scottsdale, AZ.
authors.forename: Wajih
authors.initials: W
authors.lastname: Askar
authors.affiliation: Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
authors.forename: Prakash A
authors.initials: PA
authors.lastname: Patel
authors.affiliation: Divisions of Cardiothoracic Anesthesiology and Critical Care, Duke University Medical Center, Durham, NC.
authors.forename: Kamrouz
authors.initials: K
authors.lastname: Ghadimi
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ.
authors.forename: Gerges
authors.initials: G
authors.lastname: Makar
authors.affiliation: Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
authors.forename: Jacob T
authors.initials: JT
authors.lastname: Gutsche
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ.
authors.forename: Fadi E
authors.initials: FE
authors.lastname: Shamoun
authors.affiliation: Department of Anesthesiology, Mayo Clinic, Scottsdale, AZ.
authors.forename: Harish
authors.initials: H
authors.lastname: Ramakrishna
mesh_terms: D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D000925:Anticoagulants / Q000494:pharmacology*; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001779:Blood Coagulation Factors / Q000494:pharmacology; D015942:Factor VIIa / Q000494:pharmacology; D015951:Factor Xa / Q000494:pharmacology; D065427:Factor Xa Inhibitors / Q000494:pharmacology; D006801:Humans; D010879:Piperazines / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D006435:Renal Dialysis
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D001779:Blood Coagulation Factors; D065427:Factor Xa Inhibitors; C580915:PRT064445; D010879:Piperazines; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D001120:Arginine; C000594745:idarucizumab; D015942:Factor VIIa; D015951:Factor Xa; C000593571:PER977
keywords: activated charcoal; andexanet; apixaban; aripazine; atrial fibrillation; dabigatran; direct thrombin inhibitor; edoxaban; factor Xa; idarucizumab; novel oral anticoagulants; prothrombin complex concentrates; recombinant factor VIIa; rivaroxaban; vitamin K antagonists; warfarin